Numeric Biotech is a biopharmaceutical company focused on curing rare diseases related to aging, particularly those caused by chronic inflammation. With a dedicated management team, the company is developing groundbreaking compounds that target senescent cells and reduce pro-inflammatory cytokines like IL-6. By selectively targeting the foxo4-p53 axis within the nucleus of senescent cells, Numeric Biotech's compounds have precise control over the functionality and number of regulatory T-cells (Tregs).

These compounds have the potential to become the first-in-class immunomodulators for the treatment of chronic inflammatory diseases. The management team includes experienced professionals with diverse backgrounds in regulatory affairs, medical research, and financial operations. Numeric Biotech is also supported by a distinguished Scientific Advisory Board, comprising renowned experts in genetics and molecular biology.

With their commitment to innovation and comprehensive approach to disease treatment, Numeric Biotech is at the forefront of addressing age-related conditions and offering hope to patients in need